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Abstract
Background: Hepatitis C virus (HCV) is a major cause of chronic hepatitis and hepatocellular carcinoma (HCC) and
different HCV genotypes show characteristic variations in their pathological properties. Insulin resistance (IR) occurs
early in HCV infection and may synergize with viral hepatitis in HCC development. Egypt has the highest reported
rates of HCV infection (predominantly genotype 4) in the world; this study investigated effects of HCV genotype-4
(HCV-4) on prevalence of insulin resistance in chronic hepatitis C (CHC) and HCC in Egyptian patients.
Methods: Fifty CHC patients, 50 HCC patients and 20 normal subjects were studied. IR was estimated using
HOMA-IR index and HCV-4 load determined using real-time polymerase chain reaction. Hepatitis B virus was
excluded by enzyme-linked immunosorbent assay. Standard laboratory and histopathological investigations were
undertaken to characterize liver function and for grading and staging of CHC; HCC staging was undertaken using
intraoperative samples.
Results: HCC patients showed higher IR frequency but without significant difference from CHC (52% vs 40%, p =
0.23). Multivariate logistic regression analysis showed HOMA-IR index and International Normalization Ratio
independently associated with fibrosis in CHC; in HCC, HbA1c, cholesterol and bilirubin were independently
associated with fibrosis. Fasting insulin and cholesterol levels were independently associated with obesity in both
CHC and HCC groups. Moderate and high viral load was associated with high HOMA-IR in CHC and HCC (p <
0.001).
Conclusions: IR is induced by HCV-4 irrespective of severity of liver disease. IR starts early in infection and
facilitates progression of hepatic fibrosis and HCC development.
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Introduction
Persistent Hepatitis C virus (HCV) infection is wide-
spread; it affects millions of people worldwide and
induces a range of chronic liver disease [1]. Chronic
HCV infection causes progressive hepatic fibrosis and
cirrhosis in up to 20% of patients and approximately
10%-20% of cirrhotic patients may go on to develop
hepatocellular carcinoma (HCC) within five years [2].
HCC is the most frequent cause of death in patients
infected with HCV, and epidemiological trends suggest
that the mortality rate is rising [3]. Understanding the
risk factors for HCC development in patients infected
with HCV is thus of great importance for refinement of
treatment strategies and healthcare delivery. HCV has a
high mutation rate and six major genotypes have been
characterized, each with a distinctive geographical distri-
bution and pathological properties [1]. Egypt has the
highest countrywide prevalence of HCV in the world;
about 12 to 15% of the total population are infected [4],
with HCV Genotype-4 (HCV-4) accounting for the
overwhelming majority of HCV infections.
HCV has been identified as a cause of metabolic syn-
drome, a complex that includes dyslipidemia, diabetes
and insulin resistance (IR). IR is a key feature of this
syndrome and a variety of potential molecular pathways
by which HCV may contribute to IR have been sug-
gested [5]. Patients infected with HCV have significantly * Correspondence: amalahmedhcp@yahoo.com
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and body mass index [6].
Recent studies have found that HCV-associated IR
may cause; (i) hepatic steatosis, (ii) resistance to anti-
viral treatment, (iii) hepatic fibrosis and esophageal
varices, (iv) hepatocarcinogenesis and proliferation of
HCC and (v) extrahepatic manifestations [7,8]. IR has
emerged as a risk factor for a wide variety of cancers,
including endometrial and breast (especially after meno-
pause), colon, and rectal, esophageal, kidney, pancreatic,
biliary, ovarian and cervical cancers [9]. In chronic HCV
infection, IR can favor fibrosis progression directly and
act indirectly by inducing steatosis in a genotype-depen-
dent manner [10].
It has been reported that IR can increase the risk of
developing HCC in patients with chronic HCV infec-
tion [11]. A multiplicity of viral and host factors may
play a crucial role in facilitating the onset of IR in
patients with chronic hepatitis C (CHC) that may ulti-
mately end with HCC development [5]. Given high
levels of endemic CHC infection in Egypt, and that IR is
a potentially modifiable factor, a better understanding of
correlations of IR with HCC among Egyptian patients
infected with HCV-4 is urgently needed.
The focus of the study was to investigate: (i) the pre-
valence of IR among CHC and HCC patients and its
possible role in HCC development in the context of
high prevalence of HCV-4 infection and (ii) impact of
other factors such as host characteristics (age, gender,
etc.), viral parameters (viral load, viral genotype), and
other variables including obesity and dyslipidemia on IR
and hepatic carcinogenesis.
Patients and Methods
Patients
This prospective study was conducted with 120 partici-
pants divided into three groups. The first group com-
prised 50 patients with chronic hepatitis C genotype- 4
(CHC). The second group comprised 50 hepatocellular
carcinoma (HCC) patients diagnosed and treated at Ain
Shams University Specialized Hospital, Cairo, between
February 2009 and February, 2010. A third group
included 20 apparently healthy participants who had
donated blood at the National Cancer Institute, Cairo
University.
The Ethical Committee of Ain Shams University Spe-
cialized Hospital approved the study protocol, which
was prepared in accordance with the ethical guidelines
of the 1975 Declaration of Helsinki and later revisions.
Written consent was obtained from all participants prior
to enrollment in the study and all were mentally and
physically capable of answering a questionnaire.
Inclusion criteria: adult patients of both sexes (20-70
years old), diagnosis within the previous 6 months,
positive for HCV RNA in serum (by RT-PCR assay),
with evidence of chronic hepatitis supported by liver
biopsy. The control group was made from adults nega-
tive for HCV RNA. Patients were not receiving hepatitis
treatment at the time of sampling.
The presence of HBV infection or co-infection was
excluded by serum ELISA for anti-HBc and HBsAg. In
addition to investigations needed to fulfill the selection
criteria, all individuals included in this study were sub-
jected to the following:
A. Medical History
Full history was taken with special reference to risk fac-
tors for liver diseases such as previous HCV exposure in
surgical wards, blood transfusions, dental therapy, nee-
dlestick injury, history of HCV in the spouse and i.v.
injection.
B. Physical Examination
Complete medical examination with particular focus
upon the manifestations of hepatitis such as jaundice,
hepatomegaly, and tenderness in the right hypochon-
drium. BMI was calculated as body weight in kilograms
divided by the square of height in meters (kg/m
2).
Abdominal ultrasonography was performed for all
patients.
C. Histopathological investigations
Liver biopsy specimens were formalin-fixed and paraffin
embedded then sectioned and stained (hematoxylin and
eosin) for routine histopathological examination. Grad-
ing and staging of chronic hepatitis was performed
according to Modified Knodell’s Score [12]. Liver tissues
from HCC cases were collected intraoperatively. These
samples were graded using World Health Organization
(WHO) classification criteria [13] and staging was deter-
mined according to the American Joint Committee on
Cancer [13].
D. Laboratory investigations
Venous blood samples were taken in the morning after
12-h overnight fast. Plasma glucose, HbA1c, serum ala-
nine aminotransferase (ALT), aspartate aminotransferase
(AST), gammaglutamyl transferase (GGT), albumin
(Alb), total bilirubin levels (Bil), cholesterol (Chol), and
triglycerides (TG) were measured by using Synchron
CX4 clinical system (standard clinical laboratory meth-
ods) at the Clinical Laboratory Department, Ain Shams
Specialized Hospital. Serum insulin levels and a-fetopro-
tein levels were estimated by serological techniques
(Axyam System, Abbott Laboratories).
Platelet count (Plt) and Prothrombin Time (PT) mea-
surements were performed for all patients; normal PT
was 12 seconds (100% concentration and International
Normalization Ratio (INR) of 1).
Insulin resistance (IR) was calculated on the basis of
fasting levels of plasma glucose and serum insulin,
according to the homeostasis model assessment
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followed a standard protocol; insulin resistance
(HOMA-IR) = fasting glucose (mg/dL) × fasting insulin
(μIU/mL)/405 [14]. The HOMA-IR index has seen wide-
spread use, with various cut-off values for insulin resis-
tance. In many studies of Caucasian populations a cut-
off value of 2.5 has been applied; other studies have
used higher cut-off values, for example 3.0 [15]. Genetic
variation with respect to different ethnic groups will
influence choice of cut-off value (discussed by Estegha-
mati [16]); for this study we used a cut-off value of 4.0
[17].
E. Viral Markers
ELISA assays
Sera of all patients and controls were tested for HBsAg,
anti-HBc and anti-HCV antibodies by ELISA, using
third generation kits (DiaSorin, Italy) according to the
manufacturer’s instructions.
Polymerase chain reaction (PCR) for hepatitis C virus
RT-PCR was performed as previously described [18] and
10 μl samples of the amplicons were analyzed by elec-
trophoresis (1.2% agarose gel, ethidium bromide
staining).
HCV genotyping
HCV genotype was determined using INNO-LiPAII and
III versant Kit (Innogenetics, Ghent, Belgium) according
to manufacturer’s directions
Quantitation of HCV-RNA in serum
HCV-RNA was quantitated in all patients’ serum sam-
ples using Real Time PCR (RT-PCR) [15] (primers and
RT-PCR reagents from Stratagene, Qiagen, USA). Low
viremia was defined as viral load lower than 100 x10
3
IU/L, moderate viremia as viral load 100-1000 × 10
3 IU/
L, and high viremia when viral load > 1000 x10
3 IU/
L [19].
Statistical analysis
Data was analyzed using SPSSwin statistical package ver-
sion 15 (SPSS Inc., Chicago, IL). Chi-square test (Fish-
er’s exact test) was used to examine relationships
between qualitative variables. For quantitative data,
comparison between two groups was undertaken using
Mann-Whitney test and comparison between 3 groups
with ANOVA test or Kruskal-Wallis test followed post-
Hoc “Schefe test”. Spearman-rho method was used to
test correlation between numerical variables. Multivari-
ate analysis was performed using multiple linear regres-
sion model using forward method for the significant
factors affecting fibrosis on univariate analysis. Multi-
variate analysis (logistic regression) was performed to
find the predictors for HCC development All tests are
two-tailed; a p-value<0.05 was considered significant.
Results
Baseline characteristics
(Table 1): Ages of CHC patients (median 57 years;
range 34-70 yrs) and HCC patients (median 60 years;
range 35-76 yrs) were closely comparable, while control
group participants were younger (median 35 years;
range 19-57). Preponderance of males was observed
with both CHC and HCC groups; 1:1.5 and 1:1.6
respectively. There was no significant difference
between CHC and HCC patients regarding age or sex
(p = 0.14 and 0.838, respectively). No significant differ-
ence was observed in BMI distribution between the
study groups (p = 0.908).
Biochemical, viral and pathological factors
HCC patients showed significantly higher median values
of INR and HbA1c, than CHC patients (p < 0.0001, p =
0.05, respectively), but significantly lower median values
for albumin and platelets (p < 0.001). HCC patients also
showed significantly higher median values of AST, Bil,
GGT and a-fetoprotein when compared to CHC
patients (p < 0.001 for all). No significant differences
were found between HCC and CHC patients regarding
median values of ALT, glucose, fasting insulin, HOMA-
IR index values, cholesterol and triglycerides (p = 0.09,
= 0.81, = 0.178,= 0.643,= 0.954, = 0.999).
Frequency of high value for HOMA-IR index (>4) and
presence of dyslipidemia were not significantly different
between CHC and HCC patients (Table 2).
HCC patients showed significantly higher frequency of
presentation with moderate viral load than CHC
patients (70% vs 42%, p < 0.001) and higher grades of
fibrosis (IV and V: 45/50 (90%) for HCC vs 15/50 (30%),
for the CHC group (p < 0.001).
The normal control group showed significant differ-
ence when compared to the HCC or CHC groups (p <
0.001) for all parameters studied, except BMI.
Factors associated with development of fibrosis
Multiple linear regression analysis showed that HOMA-
IR and INR are the only independent predictors of
fibrosis in CHC patients after adjustment (of age, AST,
total bilirubin, albumin, glucose, a-fetoprotein, platelets,
GGT, fasting insulin, HbA1c, cholesterol and triglycer-
ides). In HCC patients, HbA1c, triglycerides and total
bilirubin are independent predictors of fibrosis after
adjustment (of age, AST, INR, albumin, glucose, a-feto-
protein, platelets, GGT, fasting insulin, HOMA-IR and
cholesterol) Table 3. Correlation between HOMA-IR
index and grades of fibrosis in CHC and HCC groups
are shown in Figures 1 and 2, respectively.
Mohamed et al. Virology Journal 2011, 8:496
http://www.virologyj.com/content/8/1/496
Page 3 of 12Viral load and insulin resistance
Analysis of HCV viral load with HOMA-IR showed that
in the CHC group, both moderate and high viral load
were significantly associated with higher values for
HOMA-IR compared to those with lower median viral
load (4.19, 5.15 vs 1.85, p < 0.001) Figure 3. Similar dif-
ferences were not observed in HCC patients.
HCC development
Multivariate logistic regression analysis showed that
fibrosis was the only independent predictor factor for
risk of HCC development (OR: 21.64, 95%CI: 1.81-
259.09, p = 0.02), after adjustment of (age >56y,
HBA1c >7%, AST >40, TBil >1, GGT >50, INR>1)
(Table 4).
Table 1 Demographic characteristics and laboratory parameters of the study groups; normal, chronic hepatitis C (CHC)
and hepatocellular carcinoma (HCC)
Variables Control
N=2 0
CHC
N=5 0
HCC
N=5 0
*P-value
Age (Mean ± SD) 34.1 ± 9.74 55.04 ± 9.58 58.8 ± 9.66 0.14
Sex
Male: n = 69 8 30 31
Female: n = 51 12 20 19
M:F ratio 01:00.6 01:01.5 01:01.6 0.838
Obesity N(%) 8 (40%) 22 (44%) 20 (40%) 0.685
LFT
Median (Range)
ALT (IU/L) 29 (20-41) 60 (25-210) 64(34-103) 0.09
AST (IU/L) 31 (18-40) 60 (25-180) 120 (65-310) <0.001
T. Bil (mg/dL) 0.8 (0.4-1) 1 (0.5-3.6) 2.2 (1.2-6) <0.001
Albumin (g/dL) 3.9 (3.5-4.7) 3.6(1.9-4.2) 3 (1.6-3.4) <0.001
INR 0.8 (0.7-0.9) 1.1(0.7-1.5) 1.2(1.1-1.5) <0.001
GGT (IU/L) 29 (12-46) 56.5 (15-105) 190 (60-560) <0.001
Biochemical tests
Median(range),
Fasting Glu (mg/dL) 99(80-142) 170(100-230) 188(76-890) 0.81
Fasting Ins (IU/mL) 3.6(2-5.3) 8(3.5-13.0) 9(3.6-15) 0.178
HbA1c (% ) 4.2(2.7-6) 7(3.2-11.0) 8(4.2-13) 0.053
HOMA-IR 0.87(0.42-1.49) 3.42 (0.86-7.06) 4.18 (0.91-32.22) 0.643
Plt (x10
9/L) 300(152-465) 150(102-300) 130(50-170) <0.001
Cholesterol (mg/dL) 157(120-247) 190(160-270) 190(110-300) 0.954
TG (mg/dL) 153(125-254) 190(87-300) 190(120-300) 0.999
Serum AFP (ng/mL) 6 (2.9-10) 30 (5-125) 225 (150-1060) <0.001
HCV RNA
(viral load copies/IU/L) N(%) no viremia
Low** (n = 21)
Moderate (n = 56) 19(38) 2(4) <0.001
High (n = 23) 21(42) 35(70)
Stage of Fibrosis N(%) 10(20) 13(26)
I+II (n = 17) 16 (32) 1(2) <0.001
III+IV+ V (n = 83) 34 (68) 49(98)
Data are median (range), frequency (%); obesity defined as BMI>25; *P value: comparison between CHC and HCC patients. LFT, Liver function tests, ALT, alanine
aminotransferase; AST, aspartate aminotransferase; INR, International normalization ratio (for blood clotting); GGT, gammaglutamyl transferase; Glu, glucose; Ins,
insulin; HbA1c, glycosylated hemoglobin; HOMA-IR, Homeostasis Model for assessment of insulin resistance; Plt, platelet count; TG, triglycerides; AFP, alpha
fetoprotein; **Viral load (copies/IU/L): Low (<100 × 10
3), Moderate (100-1000 × 10
3), High (>1000 × 10
3)
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Obesity was significantly associated with higher HOMA-
IR index value in both CHC and HCC patients (p <
0.001). Obese patients (CHC and HCC) showed signifi-
cantly higher frequency of high viral load when com-
pared to non-obese patients (p = 0.001) Figure 4.
Multiple linear regression analysis showed that fasting
insulin and cholesterol are independent predictors for
obesity among CHC and HCC patients (OR: 1.663, p <
0.001, OR: 1.052, p < 0.001 respectively) (Table 5).
CHC and HCC with high HOMA-IR index
Table 6 shows a comparison of CHC and HCC patients
demonstrating HOMA-IR > 4. The strong similarities of
these variables suggest that HCV-4, like HCV genotypes
Table 2 Comparison of high risk variables between chronic hepatitis C (CHC) and hepatocellular carcinoma (HCC)
patients
Variables CHC
N=5 0
N(%)
HCC
N=5 0
N(%)
Odds ratio P-value
Age
>57years 20(40) 30(60) 0.44 (0.20-0.99) 0.04
Male gender 30(60) 31(62) 1.09(0.49-2.43) 0.84
Obese (BMI >25) 22(44) 20(40) 1.18(0.53-2.61) 0.68
LFT
ALT (>37 IU/L) 46(92) 47(94) 0.73(0.16-3.46) >0.99
AST (>40 IU/L) 37(74) 50(100) 1.35(1.15-1.59) <0.001
T. Bil (> 1 mg/dL) 24(48) 50(100) 2.08(1.56-2.78) <0.001
Albumin (>5.3 g/dL) 0 0
INR (> 1) 32(64) 50(100) 1.56(1.27-1.92) <0.001
GGT (>50 IU/L) 30(60) 50(100) 1.67 (1.33-2.09) <0.001
Biochemical tests
Fasting Glucose
(>110 mg/dL) 48(96) 42(84) 4.57(0.92-22.73) 0.09
Fasting Insulin (>6.IU/mL) 37(74) 42(84) 0.54 (0.20-1.45) 0.22
HbA1c (>7%) 24(48) 35(70) 0.40(0.17-0.90) 0.02
HOMA-IR (>4) 20(40) 26 (52) 1.63 (0.74-3.59) 0.23
Plt (>400 × 10
9/L) 0 0 -
Cholesterol (>200 mg/dL) 17(34) 20(40) 1.29 (0.57-2.92) 0.63
TG (> 150 mg/dL) 48(96) 47(94) 1.53(0.24-9.59) >0.99
Tumor marker
Serum AFP (>10 ng/mL) 30(12-57) 255(220-310) 26.00(6.68-101.20) <0.001
HCV RNA (viral load) N(%)
Moderate (100-1000 × 10
3) n = 56 21(42) 35(70) - <0.001
Stage of Fibrosis
III-V (n = 83) 34(68) 49(98) 23.06 (2.92-82.21) <0.001
ALT, alanine aminotransferase; AST, aspartate aminotransferase; INR, International normalization ratio (for blood clotting); GGT, gammaglutamyl transferase; Glu,
glucose; Ins, insulin; HbA1c, glycosylated hemoglobin; HOMA-IR, Homeostasis Model for assessment of insulin resistance; Plt, platelet count; TG, triglycerides; AFP,
alpha fetoprotein;
†AFP is considered elevated if greater than 400 ug/mL according to international guidelines
Table 3 Multivariate analysis of factors associated with
fibrosis in CHC and HCC patients
Factor Unstandardized coefficients t p-value
B Std.error
CHC
HOMA-IR 0.326 0.087 3.733 0.001
INR 1.806 0.812 2.225 0.031
HCC
HbA1c 0.122 0.04 3.045 0.004
TG 0.006 0.003 2.331 0.024
T.Bil 0.182 0.08 2.263 0.028
HOMA-IR, Homeostasis Model for assessment of insulin resistance; INR,
International normalization ratio (for blood clotting); HbA1c, glycosylated
hemoglobin; TG, triglycerides; T.Bil, total bilirubin
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with genotype 3.
Discussion
This study has provided valuable cues with respect to
the potential role of insulin resistance in the pathologi-
cal consequences of infection with HCV genotype 4 in a
population notable for high rates of HCV infection and
obesity. Previous studies suggest a strong synergistic
effect of metabolic factors and viral hepatitis in HCC
development in HCV-infected patients [20,21]. In con-
trast to a previous report which found association of IR,
regardless of diabetes, with development of HCC [11],
t h ep r e s e n ts t u d ys h o w e dn os i g n i f i c a n td i f f e r e n c ei n
HOMA-IR values, diabetes and insulin levels between
CHC and HCC patients. This discrepancy might be due
to confounding factors such as:
i) High prevalence of HCV-4 infection; in high preva-
lence areas the incidence of HCC is heavily influenced
by virus-related characteristics that confound other risk
factors for HCC, blurring their effect [22]. This may
indicate that the effect of IR on the risk of HCC is mod-
ified by HCV infection.
ii) High prevalence of obesity among our patients
without significant difference between CHC and HCC.
It has been documented that obesity is an independent
risk factor for IR in HCV and HCC [23].
iii) The number of participants in this study may not
have been sufficient to reveal small differences in preva-
lence in the studied population
In the present study, the frequency of conspicuous
insulin resistance (HOMA-IR >4) was 40% among CHC
patients. This finding is in agreement with Harrison and
co-workers [24], who reported that 30 to 70% of CHC
patients display some evidence of IR. These results have
suggested the occurrence of IR at early stage(s) of
chronic HCV infection irrespective of the severity of
l i v e rd i s e a s ea n dt h u st h ep o s s i b l er o l eo fI Ra sam e t a -
bolic factor that increases risk of HCC development [25].
It is noteworthy that there are a variety of plausible
Stage of Fibrosis 
HOMA-IR 
Figure 1 Correlation between HOMA-IR index and fibrosis among chronic hepatitis C patients. (r = 0.743, p < 0.001).
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and molecular pathways involved in IR development in
hepatocytes [26,27]. In turn, hyperinsulinemia that
results from IR stimulates growth of HCC and inhibits
apoptosis in diabetic patients [10,25,28].
It is very likely that a high prevalence of diabetes in
our CHC group (96%) may be a risk factor for HCC
development [25,29] but this effect may be confounded
by the underlying liver disease [22]. Veldt and co-work-
ers [25] have reported that the 5 year risk of developing
HCC is 11.4% for patients with both diabetes mellitus
and CHC with advanced fibrosis while patients without
diabetes have lower risk of HCC (occurrence of HCC in
5% after 5 years).
Multivariate analysis showed that HOMA-IR values
and INR were independently associated with fibrosis in
CHC patients, but not in the HCC patient group. This
is in accord with our hypothesis that early occurrence of
IR may hasten progression of fibrosis to cirrhosis which
may culminate in HCC development. This is consistent
with recent reports, including a Japanese cohort
study [30,31].
It has been reported that the mean IR index increases
with stage of fibrosis and may help in differentiating
fibrosis stages [32]. This was observed in our results
(Figure 1) where HOMA-IR was significantly associated
with high grades of fibrosis in CHC patients (p < 0.001).
IR promotes fibrosis progression in the liver of patients
with HCV through development of hepatic steatosis,
hyperleptinemia, increased TNF production and reduced
expression of peroxisome proliferator activated receptors
(PPAR ץ receptors) [27,33]. High levels of insulin and
glucose could promote fibrogenesis by stimulating
release of connective tissue growth factor from hepatic
stellate cells [34]. The present study did not investigate
steatosis as a possible link between IR and fibrosis.
Stage of Fibrosis 
HOMA-IR 
Figure 2 Correlation between HOMA-IR index and fibrosis among hepatocellular carcinoma patients. (r = 0.473, p = 0.001).
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total bilirubin levels were found to be independently
associated with fibrosis. This finding was not observed
in previous studies. Furthermore, multivariate analysis
showed that fibrosis was the only independent predictor
for risk of HCC development after adjustment of age
and other markers of advanced liver disease (Plt, Bil,
albumin, INR AST, GGT). These results confirm a dis-
tinct role of diabetes in HCC development [25]; in
tumorigenesis, transformed cells require more
glucose [35].
It is well established that IR is associated with abdom-
inal obesity, elevated blood cholesterol and hyperten-
sion [36]. In the present study, obesity was found
significantly associated with IR (higher HOMA-IR index
value) in both CHC and HCC patient groups (p < 0.001
compared to non-obese patients). Obesity may directly
lead to a state of chronic inflammation with consequent
increases in the expression of signaling molecules, some
of which (for example, NFKB, and fibroblast growth fac-
tor) are thought to be involved in carcinogenesis [37,38].
Chen and co-workers [21] have reported that although
Figure 3 Plot of insulin resistance (median and IQR of HOMA-IR) associated with different viral loads in chronic hepatitis C group.
Table 4 Multivariate analysis of factors associated with
risk of HCC development
Factor P Odds ratio 95.0% C.I
Age>57 0.77 0.83 0.24 2.88
HbA1c>7 0.20 .34 0.07 1.74
AST>40 1.00 7.26 0.00
TBil>1 1.00 ∞ 0.00
GGT>50 1.00 ∞ 0.00
INR>1 1.00 ∞ 0.00
Fibrosis (III-IV) 0.02 21.64 1.81 259.09
HbA1c, glycosylated hemoglobin; AST, aspartate aminotransaminase; TBil,
Total bilirubin; GGT, gammaglutamyl tranferase; INR, International
normalization ratio (for blood clotting).
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HCC, a combination of high BMI and diabetes showed
a synergistic effect. Our results confirmed a synergistic
effect of obesity when combined with high level of insu-
lin resistance (HOMA-IR index) in risk of HCC devel-
opment associated with HCV-4 infection.
Multivariate analysis in the present study showed that
fasting insulin and cholesterol were independent predic-
tors for obesity. This readily explains the prevalence of
obesity among our patients. Type 2 diabetes is a major
health problem in the Eastern Mediterranean Regional
Office (EMRO) region and many studies have estab-
lished a panel of risk factors associated with IR and type
2 diabetes; family history, body fat distribution, age, gen-
der, smoking and physical activity. Obesity and IR are
strong cofactors of HCV-related liver disease and pre-
dict lack of response to treatment [39].
Division of patient groups using age of >57 revealed
that most of our HCC patients were over 57 years in
age and the number in this age group showed significant
difference when compared to CHC patients (p = 0.04).
In univariate analysis, IR was correlated with age in
CHC patients. It has been suggested that age is asso-
ciated with a decline in mitochondrial function which
could contribute to IR [40]. However, this relationship
disappeared in multivariate analysis; this indicates that
age is one of the confounding factors for development
of IR [31].
Our HCC patients showed higher frequency of moder-
ate viral load than patients with CHC infection; a result
i na c c o r dw i t ht h a tr e p o r t e db yH s u[ 3 3 ] .O u rp a t i e n t s
(CHC or HCC) showed that moderate or high viral load
was significantly associated with high levels of insulin
resistance (high HOMA-IR index) compared to those
obesity
Obese Non-obese
M
e
d
i
a
n
 
a
n
d
 
I
Q
R
7.00
6.00
5.00
4.00
3.00
2.00
1.00
  HOMA-IR
Figure 4 Plot of median and IQR of HOMA-IR index values among obese (BMI>25) and non-obese subjects. Difference was significant (p
= 0.001).
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0.001). Interestingly, on analysis of correlation between
viral load and HOMA-IR in our CHC and HCC groups
separately, it was apparent that in the CHC patient
group, cases with moderate and high viral load were sig-
nificantly associated with higher HOMA-IR index com-
pared to those with lower viral load (4.19, 5.15 vs 1.85,
p < 0.001) while in HCC patients, moderate and high
viral loads were not significantly associated with higher
HOMA-IR values (median 4.19, 4.67 vs 3.06 p = 0.70
compared to cases with lower viral load). This observa-
tion is readily rationalized by a role of HCV infection in
production of IR before cirrhosis and HCC develop-
ment. This supports the hypothesis that a modulating
effect of HCV on insulin signaling pathways plays a role
in a separate pathway involved in the process of
hepatocarcinogenesis [41].
The association of HOMA-IR with viral load is an
important finding of the study. The patient with HCV
infection can present with IR due to metabolic and to
viral factors; the molecular bases of these effects have
been subject to intense research scrutiny though the
relative importance of some of these interrelated effects
to the clinical picture remains to be fully determined.
Chronic inflammation as a non-specific consequence of
hepatic inflammation due to HCV infection leads to IR
associated with metabolic liver disease through increased
levels of IL-1, TNF-a, IL-6 and leptin, and reduced
levels of adiponectin. This will complement obesity
effects which involve simulation of inflammatory media-
tor IkB kinase b and phosphorylation of IRS-1 [26].
Multiple pathways for direct effects of the virus on IR
have been identified. These include impairment of
Table 5 Comparison between obese and non-obese
patients (CHC and HCC)
Variables Obese
N=4 2
N(%)
Non-obese
N=5 8
N(%)
P-
value
Age 60 (36-76) 57(34-73) 0.168
Biochemical tests Median(Range),
ALT (IU/L) 60 (36-
180)
60(25-103) 0.817
AST (IU/L) 93.5(34-
310)
90(25-300) 0.115
T. Bil (mg/dL) 2.1(0.6-4.5) 1.9(0.5-6) 0.092
Albumin (g/dL) 3.1(1.6-4.2) 3.2(1.6-4.2) 0.262
INR 1.2(0.8-1.5) 1.1(0.7-1.5) <0.001
GGT (IU/L) 83.5(25-
560)
71(15-500) 0.043
Fasting Glu (mg/dL) 190((96-
890)
150 (76-870) <0.001
Fasting Ins (IU/mL) 10(6-14) 7.6 (3.5-15) <0.001
HbA1c (%) 8.6(5.2-12) 6.6 (3.2-13) <0.001
HOMA-IR 4.8(1.66-
28.5)
2.37(0.86-
32.22)
<0.001
Plt (x10
9/L) 140(50-
250)
140 (60-300) 0.018
Cholesterol (mg/dL) 220(160-
300)
187 (110-
250)
<0.001
TG (mg/dL) 212(150-
300)
180 (87-220) <0.001
Tumor marker median(range)
Serum AFP (ng/mL) 115(6-
1060)
181(5-560) 0.229
HCV RNA (viral load copies/IU/L)
N(%)
Low (<100 × 10
3)n = 21 2(4.8) 19 (32.8) 0.001
Moderate (100-1000 × 10
3) n = 56 25(59.5) 31 (53.4)
High (>1000 × 10
3) n = 23 15(35.7) 8 (13.8) 0.001
Stage of Fibrosis N(%)
I+II (n = 17) 2 (12) 15 (88) 0.02
III+IV+ V (n = 83) 40 (48) 43 (52)
ALT, alanine aminotransferase; AST, aspartate aminotransferase, INR,
International normalization ratio (for blood clotting); GGT, gammaglutamyl
transferase; Glu, glucose; Ins, insulin; HbA1c, glycosylated hemoglobin; HOMA-
IR, Homeostasis Model for Assessment of Insulin Resistance; Plt, platelet count;
TG, triglycerides; AFP, alpha fetoprotein;
Table 6 Comparison between CHC and HCC regarding
HOMA-IR index >4 and high risk variables
Variables CHC
HOMA-IR
>4
20(40%)
HCC
HOMA-IR
>4
26(52%)
Age
>57 years 13(65) 17(65)
Male gender: 14(70) 17 (65)
Obese(>25 kg/m
2) 16 (80) 17(65)
LFT (Mean ± SD)
ALT (>37 IU/L) 18(90) 24(92)
AST (>40 IU/L) 18(90) 26(100)
T. Bil (> 1 mg/dL) 13(65) 26(100)
INR (> 1-) 18(90) 26(100)
GGT (>50 IU/L) 17(85) 26(100)
Biochemical tests
Fasting glucose (>110 mg/dL) 20(100) 26(100)
Fasting insulin (>6IU/L) 20(100) 26(100)
HbA1c (>7%) 19(95) 25(96)
Cholesterol (>200 mg/dL) 14(70) 15(58)
TG(> 150 mg/dL) 20(100) 25(96)
Tumor marker
Serum AFP (>10 ng/mL) 20(100) 26(100)
HCV RNA (viral load) N(%)
Moderate 12(60) 19(73)
High 7(35) 7(27)
Stage of Fibrosis
III+IV 19(95) 26(100)
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Page 10 of 12insulin signaling through stimulation of proteosomal
inactivation of IRS-1 and IRS-2, viral induction of excess
TNF giving enhanced production of suppressor cytokine
signal proteins (SOCS) in a genotype specific man-
ner [42] which act on the Akt pathway (also down-regu-
lated by HCV-stimulated PP2A activity) giving
impairment of GLUT-4 glucose transporter activa-
tion [43]; and action of HCV core protein as an inhibi-
tor of PPAR a (peroxisome proliferator-activated
receptors) [44]. In addition, HCV NS5a protein induces
mitochondrial ROS (reactive oxygen species) production
of which activate release of a cascade of inflammatory
mediators through activation of nuclear factor-B( N F -
B) and HCV NS3, and induce endoplasmic reticulum
stress signals. Progressive fibrosis induces IR due to
impairment in insulin clearance with resulting insulin
levels [17,31].
Conclusions
Insulin resistance may be induced by HCV infection
irrespective of the severity of liver disease; insulin resis-
tance starts at an initial phase of HCV infection and
facilitates the progression of fibrosis and development of
HCC.
In chronic hepatitis C infection, HCV viral replication
per se may be dominant in the overall process of hepa-
tocarcinogenesis associated with HCV infection. This
study complements studies of HCV infection in other
populations and indicates that in the Egyptian popula-
tion suffering from a high burden of hepatitis C geno-
type-4 virus the strikingly high rates of
hepatocarcinogenisis resultf r o mac o m b i n a t i o no ft h i s
direct viral effect and the influence of an array of meta-
bolic factors resulting from virus-induced insulin
resistance.
Our results lay a foundation for a follow up cohort
study with larger sample size and including diabetic and
non-diabetic CHC patients with and without fibrosis
that would have value to illustrate the role of IR as a
separate metabolic factor for HCC development and
enable investigation of the role of other individual meta-
bolic signals such as adiponectin, and leptin which may
have particular involvement in hepatocarcinogenesis in
patients infected with HCV-4. A better understanding of
IR involvement in HCV-4 mediated HCC may point to
potential for benefit of therapeutic interventions aimed
at control of IR, and IR-associated signals, in these
patients.
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